Charcot neuroarthropathy is one of the most destructive complications of diabetes affecting the foot, yet it remains widely under-recognized in its earliest and most treatable phase. When peripheral neuropathy removes the protective sensation that normally warns a person of injury, the bones and joints of the foot can fracture, dislocate, and gradually collapse — often without the pain that would ordinarily prompt someone to seek care. The result can be permanent deformity, chronic ulceration, and, in the most serious cases, amputation. Understanding how this condition develops, why it is so often missed, and how it is managed is important for patients, caregivers, and clinicians alike.
What Is Charcot Neuroarthropathy?
Charcot neuroarthropathy — also called Charcot foot or Charcot neuro-osteoarthropathy — is the progressive destruction of the bones and joints of the foot and ankle that occurs in people with severe peripheral neuropathy. In a comprehensive 2025 review of disease mechanisms, Embaby and colleagues described the condition as multifactorial, driven by a combination of nerve damage, an exaggerated local inflammatory response, and metabolic dysregulation. Inflammatory signaling molecules such as TNF-α, IL-1β, and IL-6 promote bone resorption, weakening the architecture of the foot so that the loads of ordinary walking can trigger fractures and joint dislocation.
Although Charcot foot is often described as rare, recent epidemiological work suggests the burden is larger than once assumed. In a 2024 review, Wukich and colleagues estimated roughly 27,600 new cases each year within the United States diabetes population, with more than 200,000 people affected at any given time — an incidence the authors noted exceeds that of several common cancers. Their conclusion was that the condition is uncommon but, in their words, “not rare.”
A Diagnosis That Is Frequently Missed
The greatest danger of Charcot foot lies in how easily it is mistaken for other conditions. An acute Charcot foot usually presents as a warm, red, swollen foot — a picture that closely resembles infection (cellulitis), gout, a sprain, or a deep vein thrombosis. Because neuropathy blunts or eliminates pain, patients frequently continue to walk on the affected foot, which accelerates the structural collapse.
The consequences of this diagnostic confusion are well documented. In a retrospective cohort study of acute Charcot foot, Griffiths and Kaminski reported that 63% of patients had been initially misdiagnosed, and that symptoms had been present for a median of two months before patients reached a specialized foot service. A 2023 review by Bagheri and colleagues similarly emphasized that, in the hands of an untrained clinician, the early presentation is easily attributed to infection or arthritis — and that this delay is precisely when irreversible deformity develops.
A practical clinical clue helps distinguish Charcot foot from infection: a skin temperature difference of more than 2°C between the affected and the unaffected foot strongly suggests an active Charcot process. Plain radiographs are the first imaging step, while MRI can detect the bone marrow edema of very early disease before changes become visible on X-ray.
How the Acute Charcot Foot Is Managed
Once an acute Charcot foot is recognized, the immediate priority is to protect it from further mechanical stress. The long-standing standard of care is offloading and immobilization with a total contact cast, a closely fitted cast that redistributes pressure and limits motion while the inflammatory phase settles.
Immobilization is rarely brief. In the cohort described by Griffiths and Kaminski, the median duration of total contact casting needed to reach resolution was approximately 4.3 months, and some patients required considerably longer. Treatment is guided by serial monitoring of swelling, skin temperature, and radiographic evidence that the bones are consolidating. Once the acute phase has settled, patients generally transition to custom footwear, orthoses, or a specialized Charcot restraint orthotic walker to accommodate and support the reshaped foot.
When a foot has already developed significant instability or deformity, surgical reconstruction may be necessary. Wukich and colleagues argued for a shift in conventional thinking: because Charcot foot is fundamentally a pattern of fractures and dislocations occurring in a neuropathic limb, they suggested that surgery be considered earlier in carefully selected patients at high risk of deformity-related ulceration, rather than reserved solely for late-stage limb salvage.
Key Takeaways
The stakes of Charcot neuroarthropathy are high. Deformity from an untreated Charcot foot creates abnormal pressure points that lead to ulceration and infection, which in turn raise the risk of amputation. In a study of people with diabetes who underwent lower-limb amputation, Bandeira and colleagues found that Charcot neuroarthropathy accounted for a cumulative amputation incidence of 23.7% over five years, with a higher body mass index identified as a significant contributing factor.
The more encouraging message is that the most damaging outcomes are largely a consequence of delay rather than of the disease being untreatable. A warm, swollen foot in a person with diabetic neuropathy should be regarded as a possible Charcot foot until proven otherwise. Early recognition, prompt offloading, and timely referral to clinicians experienced in diabetic foot care remain the most effective means of preserving the structure and function of the foot and reducing the long-term risk of deformity and amputation.
References
- Embaby O, Bin Asmadi A, Binte Asmadi A, Haroun A, Mersal M, Elalfy M. Pathogenesis of Acute Diabetic Charcot Arthropathy in the Foot and Ankle: A Comprehensive Literature Review. Orthopedic Reviews. 2025;17:144007. https://doi.org/10.52965/001c.144007
- Wukich DK, Frykberg RG, Kavarthapu V. Charcot neuroarthropathy in persons with diabetes: It’s time for a paradigm shift in our thinking. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3754. https://doi.org/10.1002/dmrr.3754
- Bagheri K, Anastasio AT, Krez A, Siewny L, Adams SB. Charcot Neuroarthropathy of the Foot and Ankle in the Acute Setting: An Illustrative Case Report and Targeted Review. Western Journal of Emergency Medicine. 2023;24(5):921–930. https://doi.org/10.5811/westjem.59833
- Griffiths DA, Kaminski MR. Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study. Journal of Foot and Ankle Research. 2021;14(1):44. https://doi.org/10.1186/s13047-021-00477-5
- Bandeira MA, Dos Santos ALG, Woo K, Gamba MA, de Gouveia Santos VLC. Incidence and Predictive Factors for Amputations Derived From Charcot’s Neuroarthropathy in Persons With Diabetes. The International Journal of Lower Extremity Wounds. 2023;22(3):509–517. https://doi.org/10.1177/15347346211025893
Comments
